Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/ cyclooxygenase-1 selectivity

Journal of Medicinal Chemistry

Volumn 50, Issue 22, 2007, Pages 5403-5411

  Biava, Mariangela ^a   Porretta, Giulio Cesare ^a   Poce, Giovanna ^a   Supino, Sibilla ^b   Forli, Stefano ^b   Rovini, Michele ^b   Cappelli, Andrea ^b,c   Manetti, Fabrizio ^a,b   Botta, Maurizio ^b   Sautebin, Lidia ^d   Rossi, Antonietta ^d,e   Pergola, Carlo ^d   Ghelardini, Carla ^f   Vivoli, Elisa ^f   Makovec, Francesco ^g   Anzellotti, Paola ^h   Patrignani, Paola ^h   Anzini, Maurizio ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c European Research Centre for Drug Discovery and Development   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g Rotta Research Laboratorium   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DIARYLPYRROLE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETHYL 2 METHYL 5 [4 (METHYLSULFONYL)PHENYL] 1 (3 FLUOROPHENYL) 1H PYRROLE 3 ACETATE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NORMAL HUMAN; PATHOGENESIS; RAT; SIMULATION; SUBSTITUTION REACTION;

ACETATES; ADULT; ANIMALS; CARRAGEENAN; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; EDEMA; FEMALE; HUMANS; MALE; MICE; MODELS, MOLECULAR; PAIN MEASUREMENT; PYRROLES; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; T-BOX DOMAIN PROTEINS;

EID: 35948946191     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0707525     Document Type: Article

References (34)

1. McGettigan, P.; Henry, D. Current Problems with Non-Specific COX Inhibitors. Curr. Pharm. Des. 2000, 6, 1693-1724.
2. Kauffman, G. Aspirin-Induced Gastric Mucosal Injury: Lessons Learned from Animal Models. Gastroenterology 1989, 96S, 606-614.
3. DeWitt, D. L. COX-2-Selective Inhibitors: The New Super Aspirins. Mol. Pharm. 1999, 55, 625-631.
4. Moore, B. C.; Simmons, D. L. COX-2 Inhibition, Apoptosis, and Chemoprevention by Nonsteroidal Anti-Inflammatory Drugs. Curr. Med. Chem. 2000, 7, 1131-1144.
5. Penning, T. D.; Tally, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doctor, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
6. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Quellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The Discovery of Rofecoxib [MK 966, Vioxx, 4-(4′- Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
7. Talley, J. A; Brown, D. L.; Carter, J. S.; Masferrer, M. J.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seiberk, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
8. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, I.; Manacini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, J. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
9. Davies, I. W.; Marcoux, J.-F.; Corley, E. G.; Journet, M.; Cai, D.-W.; Palucki, M.; Wu, J.; Larsen, R. D.; Rossen, K.; Pye, P. J.; Dimichele, L.; Dormer, P.; Reider, P. J. A Practical Synthesis of a COX-2-Specific Inhibitor. J. Org. Chem. 2000, 65, 8415-8420.
10. Talley, J. Selective Inhibitors of Cyclooxygenase-2 (COX-2). Prog. Med. Chem. 1999, 36, 201-234.
11. Scheen, A. J. Withdrawal of Rofecoxib (Vioxx): What About Cardiovascular Safety of COX-2-Selective Non-Steroidal Anti-Inflammatory Drugs? Rev. Med. Liege 2004, 59, 565-569.
12. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do Selective Cyclooxygenase-2 Inhibitors and Traditional Non-Steroidal Anti-Inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-Analysis of Randomised Trials. Br. Med. J. 2006, 332, 1302-1308.
13. Chen, L. C.; Ashcroft, D. M. Risk of Myocardial Infarction Associated with Selective COX-2 Inhibitors: Meta-Analysis of Randomised Controlled Trials. Pharmacoepidemiol. Drug Saf. 2007, 16, 762-772.
14. Rodriquez, L. A.; Patrignani, P. The Ever Growing Story of Cyclooxygenase Inhibition. Lancet 2006, 368, 1745-1747.
15. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological Basis for the Cardiovascular Consequences of COX-2 Inhibition: Therapeutic Challenges and Opportunities. J. Clin. Invest. 2006, 116, 4-15.
16. Fries, S.; Grosser, T.; Price, T. S.; Lawson, J. A.; Kapoor, S.; DeMarco, S.; Pletcher, M. T.; Wiltshire, T.; FitzGerald, G. A. Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
17. Biava, M.; Porretta, G. C.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, F.; Giorni, G.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole-3-acetic Acids and Esters as Novel Classes of Potent and Selective COX-2 Inhibitors. J. Med. Chem. 2005, 48, 3428-3432.
18. Stetter, H. Catalyzed Addiction of Aldehydes to Activated Double Bonds - A New Synthetic Approach. Angew. Chem., Int. Ed. Engl. 1976, 15, 639-712.
19. Khanna, I. K.; Weier, R. M.; Paul, Y. Y.; Collins, W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
20. Garofalo, A.; Corelli, F.; Campiani, G.; Bechelli, S.; Becherucci, C.; Tafi, A.; Nacci, V. Synthesis and Biological Evaluation of Conformationally Restricted Analogs of Tolmetin and Ketorolac. Med. Chem. Res. 1994, 4, 385-395.
21. Anzini, M.; Canullo, L.; Braile, C.; Cappelli, A.; Gallelli, A.; Vomero, S.; Menziani, M. C.; De Benedetti, P. G.; Rizzo, M.; Collina, S.; Azzolina, O.; Sbacchi M.; Ghelardini, C.; Galeotti, N. Synthesis, Biological Evaluation, and Receptor Docking Simulations of 2-[(Acylamino)ethyl]-1,4-benzodiazepines as κ-Opioid Receptor Agonists Endowed with Antinociceptive and Antiamnesic Activity. J. Med. Chem. 2003, 46, 3853-3864.
22. Almansa, C.; Alfón, J.; de Arriba, A. F.; Cavalcanti, F. L.; Escamilla, I.; Gómez, L. A.; Miralles, A.; Soliva, R.; Bartrolí, J.; Carceller, E.; Merlos, M.; García-Rafanell, J. Synthesis and Structure-Activity Relationship of a New Series of COX-2 Selective Inhibitors: 1,5-Diarylimidazoles. J. Med. Chem. 2003, 46, 3463-3475.
23. Patrignani, P.; Panara, M. R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Crèminon, C.; Maclouf, J.; Patrono, C. Biochemical and Pharmacological Characterization of the Cyclooxygenase Activity of Human Blood Prostaglandin Endoperoxide Synthases. J. Pharmacol. Exp. Ther. 1994, 271, 1705-1712.
24. 2 Production in Healthy Subjects. Thromb. Res. 1980, 17, 317-327.
25. Grid, version 21; Molecular Discovery, Ltd.: Marsh Road, Pinner, Middlesex, U.K.
26. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-Inflammatory Agents. Nature 1996, 384, 644-648.
27. Panara, M. R.; Renda, G.; Sciulli, M. G.; Santini, G.; Di Giamberardino, M.; Rotondo, M. T.; Tacconelli, S.; Seta, F.; Patrono, C.; Patrignani, P. Dose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects. J. Pharmacol. Exp. Ther. 1999, 290, 276-280.
28. Xue, S.; Li, L.-Z.; Liu, Y.-K.; Guo, Q.-X. Zinc-Mediated Chain Extension Reaction of 1,3-Diketones to 1,4-Diketones and Diastereoselective Synthesis of trans-1,2-Disubstituted Cyclopropanols J. Org. Chem. 2006, 71, 215-218.
29. Zingarelli, B.; Southan, G. J.; Gilad, E.; O'Connor, M.; Salzman, A. L.; Szabò, C. The Inibitory Effects of Mercaptoalkylguanidines on Cyclooxygenase Activity. Br. J. Pharmacol. 1997, 120, 357-366.
30. Leighton, G. E.; Rodriguez, R. E.; Hill, R. G.; Hughes, J. κ-Opioid Agonists Produce Antinociception after i.v. and i.c.v. but not Intrathecal Administration in the Rat. Br. J. Pharmacol. 1988, 93, 553-560.
31. Sluka, A. K.; Westlund, K. N. Behavioral and Immunohistochemical Changes in an Experimental Arthritis Model in Rats. Pain 1993, 55, 367-377.
32. Koster, R., Anderson, M.; de Beer, E. J. Acetic Acid for Analgesic Screening. Fed. Proc. 1959, 18, 412-418.
33. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
34. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mehanics. J. Comput. Chem. 1990, 11, 440-467.